-
Mashup Score: 0Tweetorial 3: Not Just Another Monoclonal Antibody: Best Practices for Providing T-cell Therapies — Current Activities - 7 month(s) ago
Differentiating Bispecifics & CAR-T for Relapsed Refractory Multiple Myeloma Tweetorial 3: Not Just Another Monoclonal Antibody: Best Practices for Providing T-cell Therapies This activity is jointly provided by Global Education Group and Bonum…
Source: Current ActivitiesCategories: Hem/Oncs, Latest HeadlinesTweet-
#mmsm ↪️ Need on the who, what, where, how to provide #BCMA-directed T-cell tx for #Myeloma? 📚 Lots to learn w @mvmateos & me 👇#MedTweetorial🧵 🏆 🆓#CME 👉🏼https://t.co/q4DprzNF7G Supported by educational grants from @JanssenUS & @Pfizer 🏁What’s your specialty?
-
-
Mashup Score: 0Approved Risk Evaluation and Mitigation Strategies (REMS) - 7 month(s) ago
The Food and Drug Administration Amendments Act of 2007 gave FDA the authority to require a Risk Evaluation and Mitigation Strategy (REMS) from manufacturers to ensure that the benefits of a d rug or biological product outweigh its risks. The table below provides links to currently approved individual and shared system REMS. Information on historical and released REMS is available in downloadable: data files. Abecma (Idecabtagene vicleucel), suspension, for intravenous infusion BLA #125736 Idecabtagene
Source: www.accessdata.fda.govCategories: Hem/Oncs, Latest HeadlinesTweet-
@BonumCe @Global_CME @ACCCBuzz @umangtalking @JungSongCNS @jaiyesi1 @AlexSpiraMDPhD @killthecancer @KBollinMD @BSantomasso 6/Step 1️⃣Review FDA REMS program 🔗https://t.co/et2DRbxxFl 🔑REMS requirements are met by accreditation w/ @FACTcelltherapy 🔑 #CART (idecabtagene vicleucel & ciltacabtagene autoleucel) are admin'd in a cellular therapy center capable of apheresis #MMsm #MultipleMyeloma https://t.co/O26vQk1xbL
-
-
Mashup Score: 0Tweetorial #3: Best Practices with T-cell Therapy ***Post-Survey & Application for CME Credit*** - 7 month(s) ago
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Source: www.surveymonkey.comCategories: Hem/Oncs, Latest HeadlinesTweet-
@BonumCe @Global_CME @ACCCBuzz @umangtalking @JungSongCNS @jaiyesi1 @AlexSpiraMDPhD @killthecancer @KBollinMD @BSantomasso @FACTcelltherapy @BerdejaJesus @myelomaMD @FunchainMD @JanakiramMurali @SDevarakondaOSU @LNastoupilMD @ChrisLacchetti @DrJNaidoo @ANaingMD @Ccostello7 @End_myeloma @TomBmt133 @DrLauraPorter @jmikhaelmd 19/#MMsm 👀 Watch for more CME next wk! 🏆#CME👉 https://t.co/aRcyEW8Mnn 🔴#PostPoll 3⃣ 🏥Cancer center director wants to provide bispecific antibodies or CAR-T for MM Which of the following processes would need to be dev'd in order to provide both CAR-T & bispecific antibodies?
-
@BonumCe @Global_CME @ACCCBuzz @umangtalking @JungSongCNS @jaiyesi1 @AlexSpiraMDPhD @killthecancer @KBollinMD @BSantomasso @FACTcelltherapy @BerdejaJesus @myelomaMD @FunchainMD @JanakiramMurali @SDevarakondaOSU @LNastoupilMD @ChrisLacchetti @DrJNaidoo @ANaingMD @Ccostello7 @End_myeloma @TomBmt133 @DrLauraPorter @jmikhaelmd 17/ #MMsm 🏆🆓 #CME 👉 https://t.co/aRcyEW8Mnn 🔴#PostPoll 1⃣ Based on an the @ACCCBuzz survey conducted in 2020, which of the following challenges was most frequently cited as a barrier to treatment w/ bispecific antibodies?
-
-
Mashup Score: 0
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Source: www.surveymonkey.comCategories: Latest Headlines, Oncologists1Tweet-
RT @jmikhaelmd: @BonumCe @Global_CME @NoopurRajeMD @mvmateos @MaiolinoAngelo @jayrsf_ 24/🔴Post poll3️⃣ #mmsm🏆🆓#CME👉https://t.co/xZRujHjpQW…
-
-
Mashup Score: 0
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Source: www.surveymonkey.comCategories: Hematologists1, Latest HeadlinesTweet-
@NoopurRajeMD @BonumCe @Global_CME @myelomaMD @szusmani @SurbhiSidanaMD @AjaiChari @Mohty_EBMT @ravivij @PerrotAurore @nsc_natalie @Ccostello7 @MyelomaSLC @TomBmt133 @SagarLonialMD @NBahlis @CohenAd_MMdoc @End_myeloma @YiLinMDPhD @mvmateos @JoshuaRichterMD 23/🔴Post poll2️⃣ #CME👉https://t.co/2V6ClJJOP6 56-YOM dx w/ IgM MM w t(11;14). Rec'd 5 prior regimens & is triple class refractory (but has🚫had carfilzomib or pomalidomide). He's a schoolteacher w summers off & wants to avoid infusions during the school yr. Which Rx is best?
-
@NoopurRajeMD @BonumCe @Global_CME @myelomaMD @szusmani @SurbhiSidanaMD @AjaiChari @Mohty_EBMT @ravivij @PerrotAurore @nsc_natalie @Ccostello7 @MyelomaSLC @TomBmt133 @SagarLonialMD @NBahlis @CohenAd_MMdoc @End_myeloma @YiLinMDPhD @mvmateos @JoshuaRichterMD 22/🔴Post2️⃣ 🆓CME👉https://t.co/2V6ClJJOP6 71-YOF w/ IgG MM w t(4;14). Rec'd 4 prior tx inc: daratumumab, lenalidomide, bortezomib, pomalidomide, carfilzomib & isatuximab. Lives 20ml from cancer center w🚫caregiver able to travel to cellular tx center w her. Which Rx is best?
-
@NoopurRajeMD @BonumCe @Global_CME @myelomaMD @szusmani @SurbhiSidanaMD @AjaiChari @Mohty_EBMT @ravivij @PerrotAurore @nsc_natalie @Ccostello7 @MyelomaSLC @TomBmt133 @SagarLonialMD @NBahlis @CohenAd_MMdoc @End_myeloma @YiLinMDPhD @mvmateos @JoshuaRichterMD 21/🔴Post poll2️⃣ #mmsm🏆🆓CME👉https://t.co/2V6ClJJOP6 Which of the following points should be included when counseling a patient planning to receive teclistamab?
-
@NoopurRajeMD @BonumCe @Global_CME @myelomaMD @szusmani @SurbhiSidanaMD @AjaiChari @Mohty_EBMT @ravivij @PerrotAurore @nsc_natalie @Ccostello7 @MyelomaSLC @TomBmt133 @SagarLonialMD @NBahlis @CohenAd_MMdoc @End_myeloma @YiLinMDPhD @mvmateos @JoshuaRichterMD 20/🔴Post poll1️⃣ #mmsm🏆🆓CME👉https://t.co/2V6ClJJOP6 Based on the MAMMOTH & LocoMMotion study, which of following best characterizes the median OS of patients w/ MM refractory to a proteasome inhibitor, IMiD, & CD38-targeting antibody (triple class refractory)?
-
@jmikhaelmd @BonumCe @Global_CME @myelomaMD @szusmani @SurbhiSidanaMD @AjaiChari @Mohty_EBMT @ravivij @PerrotAurore @nsc_natalie @Ccostello7 @MyelomaSLC @TomBmt133 @SagarLonialMD @NBahlis @CohenAd_MMdoc @End_myeloma @YiLinMDPhD @mvmateos @JoshuaRichterMD @DrRakeshPopat @DoctorAKrishnan @ldandersonjr 23/🔴Post poll2️⃣ #CME👉https://t.co/8GsBcD5zBZ 56-YOM dx w/ IgM MM w t(11;14). Rec'd 5 prior regimens & is triple class refractory (but has🚫had carfilzomib or pomalidomide). He's a schoolteacher w summers off & wants to avoid infusions during school yr. Which Rx is best?
-
@jmikhaelmd @BonumCe @Global_CME @myelomaMD @szusmani @SurbhiSidanaMD @AjaiChari @Mohty_EBMT @ravivij @PerrotAurore @nsc_natalie @Ccostello7 @MyelomaSLC @TomBmt133 @SagarLonialMD @NBahlis @CohenAd_MMdoc @End_myeloma @YiLinMDPhD @mvmateos @JoshuaRichterMD @DrRakeshPopat @DoctorAKrishnan @ldandersonjr 22/🔴Post2️⃣ 🆓CME👉https://t.co/8GsBcD5zBZ 71-YOF w/ IgG MM w t(4;14). Rec'd 4 prior tx inc: daratumumab, lenalidomide, bortezomib, pomalidomide, carfilzomib & isatuximab. Lives 20ml from cancer center w🚫caregiver able to travel to cellular tx center w her. Which Rx is best?
-
@jmikhaelmd @BonumCe @Global_CME @myelomaMD @szusmani @SurbhiSidanaMD @AjaiChari @Mohty_EBMT @ravivij @PerrotAurore @nsc_natalie @Ccostello7 @MyelomaSLC @TomBmt133 @SagarLonialMD @NBahlis @CohenAd_MMdoc @End_myeloma @YiLinMDPhD @mvmateos @JoshuaRichterMD @DrRakeshPopat @DoctorAKrishnan @ldandersonjr 21/🔴Post poll2️⃣ #mmsm🏆🆓CME👉https://t.co/8GsBcD5zBZ Which of the following points should be included when counseling a patient planning to receive teclistamab?
-
@jmikhaelmd @BonumCe @Global_CME @myelomaMD @szusmani @SurbhiSidanaMD @AjaiChari @Mohty_EBMT @ravivij @PerrotAurore @nsc_natalie @Ccostello7 @MyelomaSLC @TomBmt133 @SagarLonialMD @NBahlis @CohenAd_MMdoc @End_myeloma @YiLinMDPhD @mvmateos @JoshuaRichterMD @DrRakeshPopat @DoctorAKrishnan @ldandersonjr 20/🔴Post poll1️⃣ #mmsm🏆🆓CME👉https://t.co/8GsBcD5zBZ Based on the MAMMOTH & LocoMMotion study, which of following best characterizes the median OS of patients w/ MM refractory to a proteasome inhibitor, IMiD, & CD38-targeting antibody (triple class refractory)?
-
-
Mashup Score: 1HCM in IBD — Current Activities - 7 month(s) ago
BCMA-directed T-cell therapies: Driving Home the Differences Between CARs & Bispecific Antibodies This activity is jointly provided by Global Education Group and Bonum CE. …
Source: Current ActivitiesCategories: Hem/Oncs, Latest HeadlinesTweet-
2/⚠️Important "need to know" bits👇 1️⃣ - read CME ℹ️👉🏼https://t.co/sAYnYHT7XH 2️⃣ - take the Pre-survey: https://t.co/5NHyH4LFpW 3️⃣ - get all the info 👇 4️⃣ - claim your 🏆 https://t.co/1mLAgkWmzF
-
2/⚠️Important "need to know" bits👇 1️⃣ - read CME ℹ️👉🏼https://t.co/DMcYrvU6fn 2️⃣ - take the Pre-survey: https://t.co/sPtjagLqwW 3️⃣ - get all the info 👇 4️⃣ - claim your 🏆 https://t.co/Es0rJiUaQ6
-
🧢s off to FDA & EMA Busy 🗓️in #MultipleMyeloma 🆕ℹ️#mmsm BCMA🎯 T-cell tx @NoopurRajeMD & me will catch u🆙 #MedTwitter #CME series w diff btwn CARs & Bispecific Antibodies 🆓CME👉🏼https://t.co/sAYnYHT7XH Supported by edu grants from @JanssenUS & @Pfizer 📍What’s ur specialty?
-
🧢s off to FDA & EMA Busy 🗓️in #MultipleMyeloma 🆕ℹ️#mmsm BCMA🎯 T-cell tx @jmikhaelmd & me will catch u🆙 #MedTwitter #CME series w diff btwn CARs & Bispecific Antibodies 🆓CME👉🏼https://t.co/DMcYrvU6fn Supported by edu grants from @JanssenUS & @Pfizer 📍What’s ur specialty?
-
-
Mashup Score: 6HCM in IBD — Current Activities - 9 month(s) ago
BCMA-directed T-cell therapies: Driving Home the Differences Between CARs & Bispecific Antibodies This activity is jointly provided by Global Education Group and Bonum CE. …
Source: Current ActivitiesCategories: Hematologists1, Latest HeadlinesTweet-
2/⚠️Important "need to know" bits👇 1️⃣ - read CME ℹ️👉🏼https://t.co/sAYnYHSA89 2️⃣ - take the Pre-survey: https://t.co/5NHyH4L7Ao 3️⃣ - get all the info 👇 4️⃣ - claim your 🏆 https://t.co/MyKSGZWgOY
-
#MedTwitter have ?s about #MultipleMyeloma BCMA🎯 T-cell tx? Don't 🥵@NoopurRajeMD & me have u covered 💃off our #mmsm #CME series w diff btwn CARs & Bispecific Antibodies 🆓CME👉🏼https://t.co/sAYnYHSA89 Supported by edu grants from @JanssenUS & @Pfizer 📍What’s ur specialty?
-
2/⚠️Important "need to know" bits👇 1️⃣ - read CME ℹ️👉🏼https://t.co/DMcYrvTypP 2️⃣ - take the Pre-survey: https://t.co/sPtjagKSHo 3️⃣ - get all the info 👇 4️⃣ - claim your 🏆 https://t.co/ErSjKgK6fj
-
#MedTwitter have ?s about #MultipleMyeloma BCMA🎯 T-cell tx? Don't 🥵@JMikhaelMD & me have u covered 💃off our #mmsm #CME series w diff btwn CARs & Bispecific Antibodies 🆓CME👉🏼https://t.co/DMcYrvTypP Supported by edu grants from @JanssenUS & @Pfizer 📍What’s ur specialty?
-
-
Mashup Score: 3BCMA-directed T-cell therapies: Driving Home the Differences Between CARs & Bispecific Antibodies Tweetorial #1 *Pre-assessment* - 9 month(s) ago
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Source: www.surveymonkey.comCategories: Hematologists1, Latest HeadlinesTweet-
@myelomaMD @szusmani @SurbhiSidanaMD @AjaiChari @Mohty_EBMT @ravivij @PerrotAurore @nsc_natalie @Ccostello7 7/🟢Pre-survey: https://t.co/5NHyH4L7Ao #mmsm @MyelomaSLC @TomBMT133 @szusmani Which of the following points should be included when counseling a patient planning to receive teclistamab?
-
3/🟢Pre-survey: https://t.co/5NHyH4L7Ao Based on the MAMMOTH & LocoMMotion study, which of following best characterizes the median OS (in months) of pts w/ #MultipleMyeloma refractory to a proteasome inhibitor, IMiD, & CD38-targeting antibody (#TripleClassRefractory)?
-
@jmikhaelmd @myelomaMD @szusmani @SurbhiSidanaMD @AjaiChari @Mohty_EBMT @ravivij @PerrotAurore @nsc_natalie @Ccostello7 7/🟢Pre-survey: https://t.co/sPtjagKSHo #mmsm @MyelomaSLC @TomBMT133 @szusmani Which of the following points should be included when counseling a patient planning to receive teclistamab?
-
@jmikhaelmd 3/🟢Pre-survey: https://t.co/sPtjagKSHo Based on the MAMMOTH & LocoMMotion study, which of following best characterizes the median OS (in months) of pts w/ #MultipleMyeloma refractory to a proteasome inhibitor, IMiD, & CD38-targeting antibody (#TripleClassRefractory)?
-
-
Mashup Score: 7
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Source: www.surveymonkey.comCategories: Hem/Oncs, Latest HeadlinesTweet-
@myelomaMD @szusmani @SurbhiSidanaMD @AjaiChari @Mohty_EBMT @ravivij @PerrotAurore @nsc_natalie @Ccostello7 @MyelomaSLC @TomBmt133 @SagarLonialMD @NBahlis @CohenAd_MMdoc @End_myeloma @YiLinMDPhD @mvmateos @JoshuaRichterMD @DrRakeshPopat @DoctorAKrishnan @ldandersonjr 22/🔴Post poll2️⃣ #CME👉https://t.co/2V6ClJJgZy 56-YOM dx w/ IgM MM w t(11;14). Rec'd 5 prior regimens & is triple class refractory (but has🚫had carfilzomib or pomalidomide). He's a schoolteacher w summers off & wants to avoid infusions during the school yr. Which Rx is best?
-
@jmikhaelmd @myelomaMD @szusmani @SurbhiSidanaMD @AjaiChari @Mohty_EBMT @ravivij @PerrotAurore @nsc_natalie @Ccostello7 @MyelomaSLC @TomBmt133 @NBahlis @CohenAd_MMdoc @YiLinMDPhD @End_myeloma @SagarLonialMD @mvmateos @JoshuaRichterMD @SLentzsch 22/🔴Post poll2️⃣ #CME👉https://t.co/8GsBcD51Mr 56-YOM dx w/ IgM MM w t(11;14). Rec'd 5 prior regimens & is triple class refractory (but has🚫had carfilzomib or pomalidomide). He's a schoolteacher w summers off & wants to avoid infusions during the school yr. Which Rx is best?
-
@myelomaMD @szusmani @SurbhiSidanaMD @AjaiChari @Mohty_EBMT @ravivij @PerrotAurore @nsc_natalie @Ccostello7 @MyelomaSLC @TomBmt133 @SagarLonialMD @NBahlis @CohenAd_MMdoc @End_myeloma @YiLinMDPhD @mvmateos @JoshuaRichterMD @DrRakeshPopat @DoctorAKrishnan @ldandersonjr 21/🔴Post2️⃣ 🆓CME👉https://t.co/2V6ClJJgZy 71-YOF w/ IgG MM w t(4;14). Rec'd 4 prior tx inc: daratumumab, lenalidomide, bortezomib, pomalidomide, carfilzomib & isatuximab. Lives 20ml from cancer center w🚫caregiver able to travel to cellular tx center w her. Which Rx is best?
-
@jmikhaelmd @myelomaMD @szusmani @SurbhiSidanaMD @AjaiChari @Mohty_EBMT @ravivij @PerrotAurore @nsc_natalie @Ccostello7 @MyelomaSLC @TomBmt133 @NBahlis @CohenAd_MMdoc @YiLinMDPhD @End_myeloma @SagarLonialMD @mvmateos @JoshuaRichterMD @SLentzsch 21/🔴Post2️⃣ 🆓CME👉https://t.co/8GsBcD51Mr 71-YOF w/ IgG MM w t(4;14). Rec'd 4 prior tx inc: daratumumab, lenalidomide, bortezomib, pomalidomide, carfilzomib & isatuximab. Lives 20ml from cancer center w🚫caregiver able to travel to cellular tx center w her. Which Rx is best?
-
@jmikhaelmd @myelomaMD @szusmani @SurbhiSidanaMD @AjaiChari @Mohty_EBMT @ravivij @PerrotAurore @nsc_natalie @Ccostello7 @MyelomaSLC @TomBmt133 @NBahlis @CohenAd_MMdoc @YiLinMDPhD @End_myeloma @SagarLonialMD @mvmateos @JoshuaRichterMD @SLentzsch 20/🔴Post poll2️⃣ #mmsm🏆🆓CME👉https://t.co/8GsBcD51Mr Which of the following points should be included when counseling a patient planning to receive teclistamab?
-
@myelomaMD @szusmani @SurbhiSidanaMD @AjaiChari @Mohty_EBMT @ravivij @PerrotAurore @nsc_natalie @Ccostello7 @MyelomaSLC @TomBmt133 @SagarLonialMD @NBahlis @CohenAd_MMdoc @End_myeloma @YiLinMDPhD @mvmateos @JoshuaRichterMD @DrRakeshPopat @DoctorAKrishnan @ldandersonjr 20/🔴Post poll2️⃣ #mmsm🏆🆓CME👉https://t.co/2V6ClJJgZy Which of the following points should be included when counseling a patient planning to receive teclistamab?
-
@myelomaMD @szusmani @SurbhiSidanaMD @AjaiChari @Mohty_EBMT @ravivij @PerrotAurore @nsc_natalie @Ccostello7 @MyelomaSLC @TomBmt133 @SagarLonialMD @NBahlis @CohenAd_MMdoc @End_myeloma @YiLinMDPhD @mvmateos @JoshuaRichterMD @DrRakeshPopat @DoctorAKrishnan @ldandersonjr 19/🔴Post poll1️⃣ #mmsm🏆🆓CME👉https://t.co/2V6ClJJgZy Based on the MAMMOTH & LocoMMotion study, which of following best characterizes the median OS of patients w/ MM refractory to a proteasome inhibitor, IMiD, & CD38-targeting antibody (triple class refractory)?
-
@jmikhaelmd @myelomaMD @szusmani @SurbhiSidanaMD @AjaiChari @Mohty_EBMT @ravivij @PerrotAurore @nsc_natalie @Ccostello7 @MyelomaSLC @TomBmt133 @NBahlis @CohenAd_MMdoc @YiLinMDPhD @End_myeloma @SagarLonialMD @mvmateos @JoshuaRichterMD @SLentzsch 19/🔴Post poll1️⃣ #mmsm🏆🆓CME👉https://t.co/8GsBcD51Mr Based on the MAMMOTH & LocoMMotion study, which of following best characterizes the median OS of patients w/ MM refractory to a proteasome inhibitor, IMiD, & CD38-targeting antibody (triple class refractory)?
-
-
Mashup Score: 10
Bispecific antibodies (BsAbs) are emerging as an important novel class of immunotherapeutic agents for the treatment of multiple myeloma (MM), and are set to be more widely used in clinical practice. However, this new class of therapies is associated with a distinct adverse event (AE) profile that i …
Source: pubmed.ncbi.nlm.nih.govCategories: Hem/Oncs, Latest HeadlinesTweet-
Sharing our consensus on this important topic @BloodCancerJnl @SagarLonialMD @mvmateos : Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: con… https://t.co/e92f8d9LBf
-
2/#MMsm @BonumCE @Global_CME ⚠️Important "need to know" items👇 1️⃣ - read CME ℹ️👉🏼https://t.co/q4DprzNF7G 2️⃣ - take the Pre-survey: https://t.co/1vp73c6uUt 3️⃣ - get all the info 👇 4️⃣ - claim your #CME 🏆 https://t.co/BITxNCTzHW